

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>		ATTY. DOCKET NO.		SERIAL NO.			
		39766-0205		10/719,310			
		APPLICANT: Paul G. Brunetta et al.					
		FILING DATE: 11/21/2003		GROUP: 1644			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
						<input type="checkbox"/>	<input type="checkbox"/>
						<input type="checkbox"/>	<input type="checkbox"/>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
Adams et al., "Humanization of a Recombinant Monoclonal Antibody to Produce a Therapeutic HER Dimerization Inhibitor, Pertuzumab" Cancer Immunotherapy, Springer-Verlag, BE, vol. 55, no. 6, pp. 717-727 (2006) XP019333247 ISSN: 1432-0851.							
Agus et al., "Targeting Ligand-Activated ErbB2 Signaling Inhibits Breast and Prostate Tumor Growth" Cancer Cell, vol. 2, pp. 127-137 (2002) XP002988666.							
Franklin et al., "Insights into ErbB Signaling from the Structure of the ErbB2-pertuzumab Complex" Cancer Cell, XX, US, vol. 5, no. 4, pp. 317-328 (2004) XP002372929 ISSN: 1535-6108.							
Jackson et al., "Blockade of Epidermal Growth Factor-or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 has Divergent Downstream Signaling and Growth Effects" Cancer Research, vol. 64, no. 7, pp. 2601-2609 (2004) XP002453734 ISSN: 0008-5472.							
Yarden et al., "Untangling the Erbb Singalling Network" Nature Reviews Molecular Cell Biology, MacMillan Magazines, London, GB, vol. 2, no. 2, pp. 127-137 (2001) XP009072338.							
EXAMINER			DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.